Influenza, Human: Clinical Trials

1687 completed, 141 unknown, 96 recruiting, 75 terminated. 492 Phase 2, 430 Phase 3, 395 Phase 1, 345 Phase 4, 329 Not applicable.

By phase and status

Phase	Trials	Status
Phase 2	492	Completed 413, Withdrawn 20, Terminated 18, Unknown 15, Recruiting 14, Not yet recruiting 7, Active not recruiting 5
Phase 3	430	Completed 356, Recruiting 18, Unknown 17, Terminated 13, Withdrawn 10, Not yet recruiting 8, Active not recruiting 4, Suspended 4
Phase 1	395	Completed 333, Recruiting 16, Unknown 13, Withdrawn 13, Terminated 9, Active not recruiting 6, Not yet recruiting 4, Enrolling by invitation 1
Phase 4	345	Completed 266, Unknown 30, Terminated 15, Active not recruiting 12, Not yet recruiting 8, Recruiting 8, Withdrawn 4, Enrolling by invitation 1, Suspended 1
Not applicable	329	Completed 234, Unknown 29, Recruiting 19, Not yet recruiting 15, Terminated 12, Active not recruiting 9, Withdrawn 6, Enrolling by invitation 5
Early Phase 1	7	Completed 5, Active not recruiting 1, Not yet recruiting 1

Follow Influenza, Human: new trials by email Literature Review of Influenza, Human trials Research Report on Influenza, Human

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
How Healthy Adults Respond to the Nasal Flu Vaccine FluMist (Live Attenuated Influenza Vaccine) - Mucosal Immune Response to Influenza Vaccination	Phase 4	Not yet recruiting	University of Alabama at Birmingham	20	2026-12-01	2026-10-13
A Human Influenza Transmission Study Using Naturally Infected Community Donors Influenza Donor Visit, Influenza Recipient Inpatient Exposures Sessions - Influenza	Not applicable	Not yet recruiting	Emory University	150	2026-12-01	2026-09-11
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS AVM0703, Placebo - ARDS, Covid19	Phase 1	Not yet recruiting	AVM Biotechnology Inc	16	2026-12-01	2025-10-02
Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections Baseline MxA testing, Serial MxA testing, MxA result feedback and antiviral treatment recommendations - Respiratory Viral Infections, Influenza	Not applicable	Not yet recruiting	Capital Medical University	618	2026-11-30	2026-10-23
A Trial of RLX-2508-102 in Healthy Volunteers RLX-2508 - Influenza	Early Phase 1	Not yet recruiting	Atridia Pty Ltd.	101	2026-11-15	2026-10-14
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older IIV-HD (standalone), NVXC19 (EU licensed, standalone), IIV-HD + NVXC19 combination - Immunization, Healthy Volunteers	Phase 3	Not yet recruiting	Sanofi	6000	2026-11-09	2026-10-22
Preoperative Pneumococcal and Influenza Vaccination to Prevent Postoperative Pulmonary Infection in Patients Undergoing Lung Resection for Pulmonary Nodules or Lung Cancer 23-valent pneumococcal polysaccharide vaccine, Quadrivalent split-virion influenza vaccine - Pneumococcal Polysaccharide Vaccine, Influenza Vaccines	Phase 4	Not yet recruiting	The First Affiliated Hospital of Guangzhou Medical University	1278	2026-11-01	2026-10-21
Immunogenicity of Standard-Dose Versus High-Dose Influenza Vaccines in Older Adults in Singapore High-dose influenza vaccine, Standard-dose influenza vaccine - Influenza	Phase 4	Not yet recruiting	Tan Tock Seng Hospital	150	2026-11-01	2026-10-20
Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region Vaccination Coverage Among Pregnant Women		Not yet recruiting	Assistance Publique - Hôpitaux de Paris	1605	2026-11-01	2026-10-20
BPL-1357 Against H1N1 Influenza Virus Challenge BPL-1357 IM, BPL-1357 IN, Placebo IM - Influenza, Human	Phase 2	Recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	129	2026-11-01	2026-10-27
Family Physician Nudges for Influenza Vaccination Among Older Adults Family Physician Influenza Vaccination Nudge - Influenza Vaccination	Not applicable	Not yet recruiting	Fudan University	3060	2026-10-24	2026-10-26
Evaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza 20 mg 102D-6 dry suspension, 40 mg 102D-6 dry suspension, Placebo - Influenza, Human	Phase 2 / Phase 3	Not yet recruiting	Capital Medical University	570	2026-10-21	2026-10-26
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants Baloxavir marboxil, Placebo - Influenza, Human, Respiratory Tract Infections	Phase 3	Recruiting	Hoffmann-La Roche	325	2026-10-16	2026-10-22
SAFE (Self-Administration of Flumist to ImprovE Uptake: A Household-Based Cluster Randomized Trial) LAIV FLUMIST - Influenza (Healthy Volunteers)	Phase 4	Not yet recruiting	McMaster University	966	2026-10-15	2026-07-31
Sequential Digital Intervention to Increase Influenza Vaccination in Patients With Heart Failure Routine Influenza Vaccination Recommendation, Repeated AI-Assisted Telephone Intervention, Gain-Framed SMS Reminder - Heart Failure, Influenza Vaccination	Not applicable	Not yet recruiting	Heart Health Research Center	588	2026-10-15	2026-10-19
A Study of Updated mRNA Seasonal Influenza Vaccines mRNA-1010, Licensed High-Dose Seasonal Influenza Vaccine - Seasonal Influenza	Phase 4	Not yet recruiting	ModernaTX, Inc.	200	2026-10-15	2026-10-20
A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza. SYH2085, Placebo - Influenza	Phase 2	Not yet recruiting	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	213	2026-10-10	2026-09-01
A Study to Evaluate the Immune Responses of Subunit Influenza Vaccine in Healthy Adults Group A, Group B - Influenza	Phase 4	Active not recruiting	Ab&B Bio-tech Co., Ltd.JS	138	2026-10-10	2026-10-16
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates cH15/3, cH4/3, cH5/1N1 - Influenza	Phase 1	Not yet recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	60	2026-10-09	2026-10-23
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children mRNA-1010, Fluarix Trivalent - Seasonal Influenza	Phase 1	Not yet recruiting	ModernaTX, Inc.	96	2026-10-07	2026-10-13

Showing 20 of 2160. Sign in to see all of them.

Narrower conditions

COVID-19 (113)  ·  Virus Diseases (97)  ·  Respiratory Tract Infections (88)  ·  Orthomyxoviridae Infections (72)  ·  Influenza in Birds (68)  ·  Infections (53)  ·  Common Cold (47)  ·  Pneumonia (34)  ·  Respiratory Tract Diseases (26)  ·  Coronavirus Infections (20)  ·  RNA Virus Infections (20)  ·  Respiratory Syncytial Virus Infections (17)  ·  Whooping Cough (16)  ·  HIV Infections (15)

Broader conditions

RNA Virus Infections (2140)  ·  Respiratory Tract Diseases (2134)  ·  Infections (2107)  ·  Orthomyxoviridae Infections (2088)  ·  Respiratory Tract Infections (2072)  ·  Virus Diseases (2063)  ·  Lung Diseases (170)  ·  Coronaviridae Infections (126)  ·  Nidovirales Infections (126)  ·  Pneumonia (122)  ·  Pathological Conditions, Signs and Symptoms (121)  ·  Pneumonia, Viral (112)  ·  Coronavirus Infections (106)  ·  Pathologic Processes (87)  ·  Animal Diseases (68)

Interventions

Influenza Vaccines (424)  ·  Oseltamivir (86)  ·  FluMist (60)  ·  fluarix (52)  ·  vaxigrip (47)  ·  Vaccines (33)  ·  Sodium Chloride (31)  ·  baloxavir (22)  ·  fluad vaccine (21)  ·  Fluzone High-Dose (16)  ·  FluBlok (15)  ·  Saline Solution (15)  ·  Zanamivir (14)  ·  Adjuvants, Pharmaceutic (13)  ·  mRNA-1010 influenza vaccine (13)

Sponsors

GlaxoSmithKline (184)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (173)  ·  Sanofi Pasteur, a Sanofi Company (116)  ·  Novartis Vaccines (59)  ·  Seqirus (51)  ·  MedImmune LLC (41)  ·  Stanford University (29)  ·  Alachua Government Services, Inc. (24)  ·  Novartis (24)  ·  ModernaTX, Inc. (22)  ·  Sanofi (22)  ·  Hoffmann-La Roche (20)  ·  Crucell Holland BV (18)  ·  The University of Hong Kong (18)  ·  Sinovac Biotech Co., Ltd (17)

Countries

United States (912)  ·  Canada (147)  ·  China (137)  ·  United Kingdom (137)  ·  Germany (108)  ·  France (95)  ·  Belgium (92)  ·  Australia (83)  ·  Russia (62)  ·  Spain (59)  ·  South Korea (53)  ·  Poland (49)  ·  Italy (45)  ·  Taiwan (44)  ·  Thailand (44)

Top investigators

Robert Walker, MD (16)  ·  Cornelia Dekker, MD (14)  ·  Matthew J Memoli, M.D. (10)  ·  Melissa Stockwell, MD MPH (8)  ·  Stephen Quake, PhD (8)  ·  Xiaosong He, PhD (8)

Results publications

PMID 28963118, PMID 33215698, PMID 36715243, PMID 39756216, PMID 19261173, PMID 21857263, PMID 26432909, PMID 26787832, PMID 28325769, PMID 29443825, PMID 29465480, PMID 29706550, PMID 30066805, PMID 32379201, PMID 32526188, PMID 39550717, PMID 42834081, PMID 18420314, PMID 18599164, PMID 19540952, PMID 19588665, PMID 20018364, PMID 20018365, PMID 21352939, PMID 21378375, PMID 21615847, PMID 21906647, PMID 22172502, PMID 22418809, PMID 22537984, PMID 22542645, PMID 22872731, PMID 22885014, PMID 22906937, PMID 24041010, PMID 24606983, PMID 25004134, PMID 25148380, PMID 25184864, PMID 25222307, PMID 26042486, PMID 26069949, PMID 26176592, PMID 26275339, PMID 26391974, PMID 27746226, PMID 28369198, PMID 28446441, PMID 29100706, PMID 29253090

NIH funding

2009 (23), U19AI057229 (20), 2008 (12), 2015 (10), 2016 (8), 2018 (7), R01AI135029 (7), 2023 (6), 2014 (5), P30AG034532 (5), 2025 (4), U19AI090019 (4), 2017 (3), 2019 (3), N01AI30025 (3)